1. Academic Validation
  2. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies

  • Bioorg Med Chem Lett. 2016 Aug 15;26(16):4036-41. doi: 10.1016/j.bmcl.2016.06.078.
Jun Liang 1 Birong Zhang 2 Sharada Labadie 2 Daniel F Ortwine 2 Maia Vinogradova 2 James R Kiefer 2 Victor S Gehling 3 Jean-Christophe Harmange 3 Richard Cummings 3 Tommy Lai 4 Jiangpeng Liao 4 Xiaoping Zheng 4 Yichin Liu 2 Amy Gustafson 2 Erica Van der Porten 2 Weifeng Mao 4 Bianca M Liederer 2 Gauri Deshmukh 2 Marie Classon 2 Patrick Trojer 3 Peter S Dragovich 2 Lesley Murray 2
Affiliations

Affiliations

  • 1 Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: liang.jun@gene.com.
  • 2 Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
  • 3 Constellation Pharmaceuticals Inc., 215 First Street, Suite 200, Cambridge, MA 02142, USA.
  • 4 WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Abstract

Starting with a lead [1,5-a]pyrimidin-7(4H)-one-containing molecule (1), we generated potent, selective and orally bioavailable KDM5 inhibitors. Using structure- and property-based approaches, we designed 48 with improved cell potency (PC9 H3K4Me3 EC50=0.34μM). Furthermore, 48 maintained suitable physiochemical properties and displayed an excellent pharmacokinetic (PK) profile in mice. When dosed orally in mice at 50mg/kg twice a day (BID), 48 showed an unbound maximal plasma concentration (Cmax) >15-fold over its cell EC50, thereby providing a robust chemical probe for studying KDM5 biological functions in vivo.

Keywords

Drug resistance; Epigenetics; Histone demethylase; KDM5; Lead optimization; Selective KDM5 inhibitors.

Figures
Products